PerspectiveRestrictive chronic lung allograft dysfunction: Where are we now?
Section snippets
History
In 1984, Burke et al were the first to describe the presence of obliterative bronchiolitis (OB) in patients with a ventilatory defect after heart-lung transplantation. OB is a fibroproliferative obliteration of the small airways and, in subsequent decades, it was considered to be the hallmark of chronic rejection. However, these patients did not show a typical, purely obstructive, ventilatory defect and suffered at least partially from restrictive physiology as a decrease in total lung capacity
Diagnosing rCLAD
There is currently no internationally approved definition for rCLAD, but several groups attempted to discriminate a form of rCLAD by using different diagnostic criteria. Woodrow et al made a distinction within CLAD patients (single and double LTx) based on the presence of pleuroparenchymal infiltrates on chest computed tomography (CT) scan and the pattern of decline in forced vital capacity (FVC). First, they made a distinction between “non-specific” CLAD (pleuro-parenchymal infiltrates
Prevalence and prognosis of rCLAD
Woodrow et al undertook an important study investigating non-specific CLAD patients using a combination of imaging and spirometry.11 Patients with persistent pleuroparenchymal infiltrates on CT were denominated “non-specific” CLAD (35%), whereas “specific” CLAD patients (no pleuroparenchymal infiltrates) were divided into restrictive BOS (28%) and obstructive BOS (37%) patients. There was no survival difference, however, between “non-specific” and “specific” CLAD patients and no difference
Radiology of rCLAD
All reports on rCLAD demonstrated radiologic alterations of interstitial lung disease.12, 13, 14 Typical characteristics included (traction-)bronchiectasis, central and peripheral consolidation, pleural thickening and volume loss, with most patients showing an upper lobe-dominant fibrotic pattern.12, 14 One surprising finding was that half of the rCLAD patients already demonstrated parenchymal alterations on chest CT scan before CLAD onset. This demonstrates that patients with persistent
Pathology of rCLAD
Histopathologic analysis of explanted lungs and open lung biopsies of patients with rCLAD revealed pleuroparenchymal fibroelastosis, characterized by hypocellular collagen deposition with thickening of the septa.20 This collagen accumulation was mainly situated in the sub-pleural space, but centrilobular and paraseptal collagen distribution was also observed. A sharp demarcation between “healthy” and diseased zones was present. Remarkably, almost all specimens also showed OB lesions, indicating
Risk factors and mechanism
The risk factors and mechanisms of rCLAD remain mostly elusive as no comprehensive studies have been performed to date. Females were more predisposed to develop rCLAD in the study by Todd et al,14 but no other studies have confirmed their findings. Similarly, patients developing rCLAD were also younger in the study by Verleden et al and tended to be younger in the study by Sato et al,12, 13 but this was not confirmed in other studies.14, 16 Similarly, cytomegalovirus mismatch seemed to
Treatment
Pirfenidone is an anti-fibrotic drug and, in some countries, has been approved as the first treatment option for idiopathic pulmonary fibrosis.28 Recently, a case report demonstrated the potential of pirfenidone for slowing the evolution of rCLAD.19 Another drug that could be beneficial is alemtuzumab (Campath-1H), which is an antagonist of CD52, a protein expressed on B-cells, lymphocytes, dendritic cells and monocytes. This drug was found to improve interstitial changes and lung function in 4
Phenotyping CLAD: Near the end or just starting?
There is a clear need for studies confirming the prognosis of rCLAD, as well as internationally approved diagnostic criteria for rCLAD. This would spur the initiation of multicenter trials to investigate risk factors and mechanisms in more depth. In addition, there is a need for studies comparing spirometric evolution (FEV1, FVC, FEV1/FVC and TLC) with radiology and pathology to establish the degree of overlap between the different diagnostic criteria for rCLAD. Indeed, we are only in the phase
Disclosure statement
The authors have no conflicts of interest to disclose. This study was supported by the Research Foundation Flanders (12G8715N to S.E.V.; KAN2014 1.5.139.14 to R.V.; G.0723.10, G.0679.12 and G.0679.12 to G.M.V.) and Onderzoeksfonds KU Leuven (OT/10/050 to G.M.V.).
References (32)
- et al.
A new classification system for chronic lung allograft dysfunction
J Heart Lung Transplant
(2014) - et al.
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation
Chest
(1984) - et al.
Pathologic pulmonary alterations in long-term human heart-lung transplantation
Hum Pathol
(1985) - et al.
Physiologic aspects of human heart-lung transplantation. Pulmonary function status of the post-transplanted lung
Chest
(1984) - et al.
The pathology of combined heart-lung transplantation: an autopsy study
Hum Pathol
(1988) - et al.
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria
J Heart Lung Transplant
(2002) - et al.
Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients
Chest
(2006) - et al.
Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation
J Heart Lung Transplant
(2005) - et al.
Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation
J Heart Lung Transplant
(2010) - et al.
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction
J Heart Lung Transplant
(2011)